What we’ve learned from three years of fighting COVID-19

Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...
Read More
WTAS: Inflation Reduction Act already impacting R&D decisions

The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...
Read More
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

On September 28-29, 2022, PhRMA hosted the second annual Pathways to Success: Virtual Graduate Summit and Career Expo. This event provided a unique opportunity for students and faculty from diverse...
Read More
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...
Read More
Congratulations to our 2022 Working for Cures Employee Champions

The Working for Cures Employee Champion Awards celebrate the real people in our industry who go above and beyond to advance science and support the work our industry does for patients.
Read More
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...
Read More
An open letter to Congress: Stand with patients and future cures

I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:
Read More
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a...
Read More
Biopharmaceutical researchers to discuss the value of R&D with Congress

Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in bringing new treatments...
Read More
A conversation with Barry Greene, CEO of Sage Therapeutics

Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...
Read More